OncRef

Clinical Trial: NCT05828082

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-07-31

Study Overview

Brief Summary

This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein (SPOP). M1774 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving M1774 may be able to shrink or stabilize refractory SPOP-mutant prostate cancer.

Official Title

A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer

Conditions

Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

Intervention / Treatment

  • Procedure: Biopsy Procedure
  • Procedure: Biospecimen Collection
  • Procedure: Computed Tomography
  • Procedure: Magnetic Resonance Imaging
  • Procedure: Positron Emission Tomography
  • Drug: Tuvusertib
  • Procedure: Ultrasound Imaging

Other Study ID Numbers

  • NCI-2023-03150
  • NCI-2023-03150
  • 10603
  • 10603
  • UM1CA186709

Start Date (Actual)

2023-10-16

Primary Completion Date (Estimated)

2027-01-01

Study Completion Date (Estimated)

2027-01-01

Enrollment (Estimated)

20

Study Type

Interventional

Phase

Phase 2